<p><strong>纽约，NY / ACCESS Newswire /2025 年 8 月 10 日/</strong> 如果您在 <strong>Biohaven Ltd.</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
<p>https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28</p>
<p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
<p><strong>诉讼：</strong> 针对 Biohaven Ltd.提起了一项集体诉讼，旨在追回在 2023 年 3 月 24 日至 2025 年 5 月 14 日期间因涉嫌证券欺诈而受到不利影响的股东的损失。</p>
<p><strong>案件详情：</strong> 提交的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(i) 该公司的产品候选药物 troriluzole 作为 SCA 治疗的监管前景和/或 Biohaven 为支持 troriluzole 在该适应症下的监管批准所提交的数据的充分性被夸大；(ii) BHV-7000 作为双相情感障碍治疗的疗效和临床前景同样被夸大；(iii) 一旦上述所有情况被揭露，可能会对 Biohaven 的业务和财务状况产生重大负面影响；(iv) 因此，被告的公开声明在所有相关时间都是实质性虚假和误导的。</p>
<p><strong>接下来会发生什么？</strong> 如果您在相关时间段内在 Biohaven Ltd.股票中遭受损失——即使您仍持有股票——请访问 https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28 以了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
<p><strong>为什么选择 LEVI &amp; KORSINSKY：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>纽约，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>电话：(212) 363-7500</p>
<p>传真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

Biohaven药业

<p>Levi & Korsinsky LLP 正在敦促在 Biohaven Ltd. (BHVN) 上亏损的投资者在 2025 年 9 月 12 日之前采取行动，参与与涉嫌证券欺诈相关的集体诉讼。诉讼声称该公司对其产品候选者做出了虚假陈述，这对其业务和财务状况产生了负面影响。鼓励在 2023 年 3 月 24 日至 2025 年 5 月 14 日之间遭受损失的投资者寻求无任何费用或义务的赔偿。Levi & Korsinsky 在证券诉讼方面有着良好的业绩记录</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / August 10, 2025 /</strong> If you suffered a loss on your <strong>Biohaven Ltd.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p><strong>纽约，NY / ACCESS Newswire /2025 年 8 月 10 日/</strong> 如果您在 <strong>Biohaven Ltd.</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
</div><p>https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Biohaven Ltd. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025.</p>
<div class="lb-trans"><p><strong>诉讼：</strong> 针对 Biohaven Ltd.提起了一项集体诉讼，旨在追回在 2023 年 3 月 24 日至 2025 年 5 月 14 日期间因涉嫌证券欺诈而受到不利影响的股东的损失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.</p>
<div class="lb-trans"><p><strong>案件详情：</strong> 提交的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(i) 该公司的产品候选药物 troriluzole 作为 SCA 治疗的监管前景和/或 Biohaven 为支持 troriluzole 在该适应症下的监管批准所提交的数据的充分性被夸大；(ii) BHV-7000 作为双相情感障碍治疗的疗效和临床前景同样被夸大；(iii) 一旦上述所有情况被揭露，可能会对 Biohaven 的业务和财务状况产生重大负面影响；(iv) 因此，被告的公开声明在所有相关时间都是实质性虚假和误导的。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Biohaven Ltd. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下来会发生什么？</strong> 如果您在相关时间段内在 Biohaven Ltd.股票中遭受损失——即使您仍持有股票——请访问 https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28 以了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 LEVI &amp; KORSINSKY：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>纽约，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

您是否在 Biohaven Ltd. (BHVN) 上遭受了损失？Levi & Korsinsky 敦促投资者在2025年9月12日之前采取行动